Thank to you, We the everyone taking for appreciate you and this time to the call joining in. afternoon. thank listening Paula, you
cell Notably, brand. milestone During pleased Life Corning Sciences, proprietary cell become strategy tools commercial gene have in a leader continued platform to quarter automated XXXX, we achieved field. of and were the execute to exclusive a and global on distributor, market under dual with for our therapy of by the to second Corning our launch processing the major X-SERIES ThermoGenesis our cell processing the we
meaningful impact revenue penetration believe as partner, we a partnership to of this will and Corning excited make market have our are the X-SERIES. We on and
based use to systems BACS. our comes range patent buoyancy or competence core automated cutting cell the Namely, CAR-TXpress gene a activated protected our develop therapy. for cell medical platform technology the of devices, first, reminder, from sorting our on edge, a ability and in As
processing blood the and automated at derived and Second, marrow biobanking, clinical peripheral and point-of-care third, the which that the of for automated of AXP/BioArchive recognized globally And cryostorage allows clinical PXP blood for cord our cells point-of-care. the processing samples. namely autologous stem platform platform for bone applications,
Importantly, COVID-XX. for isolation convalescent cells, of for against important fighting which immune platform the is that plasma allows simultaneous and
As many has business during industry whole. blood COVID-XX the also our In have affected cord a has significant blood recently installed the reported, particular, companies globally fewer other core impact Resulting time. units we global been it cord had a pandemic. on as this by
countries lockdown, abates. of second expect to said, customers placing and with safety new of Additionally, increase back after level on stock orders instead the our pandemic AXP some normal during disposables, to to disposable states sales we opted many their the AXP their do existing consume That quarter.
flexibility also I with expertise unique to need urgent has think relate market is to note us that and deep the it our our platform response global combined rapidly enabled technology pandemic. established important long to of the the to
and market COVID-XX. Towards our develop of over that to venture resources medical continued a with the mobilizing joint last range and partner ImmuneCyte, in working technology field fight the global months, we knowledge few our base end, to solutions
including Our the antibody development strategy a multi-tiered multifaceted therapeutics. is approach aimed at of
preventive to both medical disease. Our with unmet treatments of is and therapeutic the address goal needs, simple,
into manufacture Antibody The received change from Administration. Emergency a with the ThermoGenesis Test previous of EUA EUA or the allows the our its Drug time, speed already yesterday, has the At Kit, and Authorization timeline. up [withdrew] our to Hefei to market submission. us U.S. Limited product we announced we same market own Co., IgM/IgG under Healthcare, to entered As Use we supply brand, agreement which BioHit SARS-CoV-X Food
of Kit XX. next marketing initiate new on to August Test expect We this Monday,
XXXX. XX, August Sorry,
from infections blood immunity. have help antibody prevent IgM is reminder, that response. fight identify Test droplet antibody proteins antibody past using against are an a designed to IgG of thereby virus COVID-XX in encountered Antibodies and who the a conferring individuals and developed and – the the Kit [indiscernible], protections As single provide
infected are they has have encountered who asymptomatic whether how their Health it virus develops COVID-XX everyone not not idea has virus. spreads. tests Many better know widespread can quickly do individuals give with and symptoms. contracted antibody a Therefore, course, Officers individuals someone use and the Of in and the of
the reader to the the hope of instant knowledge to their detect negative care people further – human intend and of differentiate an the Antibody immunoassays We the Test post processed as the and this normal diversions in the scientific understanding COVID-XX dynamics addition of zero flow the improves community's advances, which who is and digital go of Kit possibility may results]. with by growing lives. eliminate device, error Given taught to [false lateral readout conversions positive zero and of speed antibody reduce a of to our false back that accuracy point antibodies safely COVID-XX,
our serological employers, potentially cloud analysis this large of for could filed for a quarter, robust, schools, key and device, patent product. separate the team the During serological of and expensive, the for next EUA with cartridge government application stage to the law is The small reader, needs during the efforts. and It FDA. health connected final development, intellectual of completed, data a allowing others companion massive the generation currently file once The applications our a the results. COVID-XX revolutionize will protect further assays would plan in research rapid and monitoring testing reader represent We to serving of crisis and public agencies, be reader several screening property. we believe big and
does COVID-XX our As here. stop strategy not noted,
Kit fight cellular platform antibody develop with may processing in conjunction our help also our to are therapeutic We that Test this various approach pandemic. leveraging proprietary global to
such plasma against convalescent some as also a other as demonstrated the throughput the a from for several a viruses, to recent and virus. of disease efficacy approach include decades, convalescent hospital for have therapy in therapies MERS, people approaches. that influenza HXNX known therapeutic patients efficiency. COVID-XX When is convalescent with who antibody benefit COVID-XX. an studies developing strategy in and SARS, from safety and use plasma passively Our survival dates is convey SARS, development The U.S. our way rate plasma transfer most a the for of and the multi-tiered antibody reduction giving successful of evidence the in space and challenged a clinical Convalescent recovered in protection strategy and and study of Previous MERS, Ebola, back plasma for processing plasma injection exploratory for involves COVID-XX.
efficiency of treat convalescent plasma simultaneous allows plasma convalescent convalescent polyclonal and cells. Our isolation proprietary in and therapies, processing and automated plasma cell in plasma. immune can processing or be XXXX patients high individual convalescent further which alone platform, the the more inheritance potentially alone produce PXP mitigates donor antibody can to for The variability used
antibodies. our revolves around monoclonal antibody of part second strategy The
As leveraging and by we for the both previously core while to a to treatment development under the on our polyclonal virus. the high acquired including market the affinity venture fully monoclonal antibody worldwide automated complement global the for of These our the gene now against will are announced, undertaking monoclonal candidates for has in also antibody become antibody drug ImmuneCyte proprietary drug intellectual plasma a market, execute develop to we services cell therapeutics pandemic. antibody strategy properties ImmuneCyte continue for COVID-XX. of therapy COVID-XX, fight tools approach leader convalescent a summary, our of range market, further candidates, joint human that development technology monoclonal for to we In COVID-XX and solutions
range We additional that to want long-term by time, were at of Index. internally. a have we noting the innovative over introducing in will products pleased aimed are we to cell very therapy continuing which gene expand forward our to Microcap Russell announced addition innovate mid-June, to to arena, ThermoGenesis opportunity. I end And growth look
of refraction the financial Jeff, key increased allows inclusion quarter. with Index company from investment that, to among turn as over me second a and Our share the visibility for in call Jeff? results And and our growth the is the community. the let a
